Suppr超能文献

多区域临床试验:日本对药物研发策略及日本受试者样本量的观点

Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.

作者信息

Ando Yuki, Uyama Yoshiaki

机构信息

Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

出版信息

J Biopharm Stat. 2012 Sep;22(5):977-87. doi: 10.1080/10543406.2012.701581.

Abstract

Multiregional clinical trials including Japanese subjects are playing a key role in new drug development in Japan. In addition to the consideration of differences in intrinsic and extrinsic ethnic factors, deciding the sample size of Japanese subjects is an important issue when a multiregional clinical trial is intended to be used for Japanese submission. Accumulated experience suggests that there are several points to consider, such as the basic principles described in the guidance document, drug development strategy, trial phase, and disease background. The difficulty of interpreting the results of Japanese trials should also be considered.

摘要

包括日本受试者在内的多区域临床试验在日本新药研发中发挥着关键作用。除了考虑内在和外在种族因素的差异外,当多区域临床试验旨在用于日本申报时,确定日本受试者的样本量是一个重要问题。积累的经验表明,有几个要点需要考虑,例如指导文件中描述的基本原则、药物研发策略、试验阶段和疾病背景。还应考虑解读日本试验结果的难度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验